In vivo videomicroscopy reveals differential effects of the vascular-targeting agent ZD6126 and the anti-angiogenic agent ZD6474 on vascular function in a liver metastasis model

Angiogenesis

Volumn 7, Issue 2, 2004, Pages 157-164

  Varghese, Hemanth ^a   MacKenzie, Lisa ^b   Groom, Alan ^a   Ellis, Christopher ^a   Ryan, Anderson ^c   MacDonald, Ian ^a   Chambers, Ann ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b London Regional Cancer Centre   (Canada)

^c UK   (United Kingdom)

Author keywords

anti angiogenesis; vascular targeting; VEGF; ZD6126; ZD6474

Indexed keywords

ANGIOGENESIS INHIBITOR; N ACETYLCOLCHINOL PHOSPHATE; RAS PROTEIN; VANDETANIB; VASCULAR TARGETING AGENT;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BLOOD FLOW; COMBINED IMMUNODEFICIENCY; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; FEMALE; FIBROBLAST; HISTOLOGY; IN VIVO STUDY; LIVER METASTASIS; MESENTERIC VEIN; MICROSCOPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL; TUMOR NECROSIS; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; APOPTOSIS; BLOOD VESSELS; CELL LINE, TRANSFORMED; DISEASE MODELS, ANIMAL; FEMALE; LIVER NEOPLASMS; MICE; MICE, SCID; MICROSCOPY, VIDEO; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; ORGANOPHOSPHORUS COMPOUNDS; PIPERIDINES; QUINAZOLINES;

ANIMALIA;

EID: 8544257360     PISSN: 09696970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10456-004-1941-3     Document Type: Article

References (30)

1. Folkman J. Clinical applications of research on angiogenesis. N Engl J Med 1995; 333: 1757-63.
2. Folkman J. Incipient angiogenesis. J Natl Cancer Inst 2000; 92: 94-5.
3. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407: 249-57.
4. Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2002; 2: 563-72.
5. Kerbel RS. Tumor angiogenesis: Past, present and the near future. Carcinogenesis 2000; 21: 505-15.
6. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002; 2: 727-39.
7. Shepherd FA, Sridhar SS. Angiogenesis inhibitors under study for the treatment of lung cancer. Lung Cancer 2003; 41: S63-S72.
8. Glade-Bender J, Kandel JJ, Yamashiro DJ. VEGF blocking therapy in the treatment of cancer. Expert Opin Biol Ther 2003; 3: 263-76.
9. Thorpe PE. Vascular targeting agents as cancer therapeutics. Clin Cancer Res 2004; 10: 415-27.
10. Micheletti G, Poli M, Borsotti P et al. Vascular-targeting activity of ZD6126, a novel tubulin-binding agent. Cancer Res 2003; 63: 1534-7.
11. Blakey DC, Ashton SE, Westwood FR et al. ZD6126: A novel small molecule vascular targeting agent. Int J Radiat Oncol Biol Phys 2002; 54: 1497-502.
12. Blakey DC, Westwood FR, Walker M et al. Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models. Clin Cancer Res 2002; 8: 1974-83.
13. Goto H, Yano S, Zhang H et al. Activity of a new vascular targeting agent, ZD6126, in pulmonary metastases by human lung adenocarcinoma in nude mice. Cancer Res 2002; 62: 3711-5.
14. Davis PD, Dougherty GJ, Blakey DC et al. ZD6126: A novel vascular-targeting agent that causes selective destruction of tumor vasculature. Cancer Res 2002; 62: 7247-53.
15. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9: 669-76.
16. Du JR, Jiang Y, Zhang YM, Fu H. Vascular endothelial growth factor and microvascular density in esophageal and gastric carcinomas. World J Gastroenterol 2003; 9: 1604-6.
17. Mukherjee T, Kumar A, Mathur M et al. Ets-1 and VEGF expression correlates with tumor angiogenesis, lymph node metastasis, and patient survival in esophageal squamous cell carcinoma. J Cancer Res Clin Oncol 2003; 129: 430-6.
18. Wedge SR, Ogilvie DJ, Dukes M et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 2002; 62: 4645-55.
19. Varghese HJ, Davidson MT, MacDonald IC et al. Activated ras regulates the proliferation/apoptosis balance and early survival of developing micrometastases. Cancer Res 2002; 62: 887-91.
20. Varghese HJ, MacKenzie LT, Ellis CG et al. In vivo quantification of functional microcirculation in liver metastases. Proc Am Assoc Cancer Res 2003; 44: 779.
21. Japee SA, Ellis CG, Pittman RN. Flow visualization tools for image analysis of capillary networks. Microcirculation 2004; 11: 39-54.
22. Weibel ER. Profile size and particle size. In Weibel ER (ed): Stereological Methods: Practical Methods for Biological Morphometry, Vol. 1. New York: Academic Press 1979; 51-60.
23. Luzzi KJ, Varghese HJ, MacDonald IC et al. Inhibition of angiogenesis in liver metastases by carboxyamidotriazole (CAI). Angiogenesis 1999; 2: 373-9.
24. Siemann DW, Rojiani AM. Enhancement of radiation therapy by the novel vascular targeting agent ZD6126. Int J Radiat Oncol Biol Phys 2002; 53: 164-71.
25. Siemann DW, Rojiani AM. Antitumor efficacy of conventional anticancer drugs is enhanced by the vascular targeting agent ZD6126. Int J Radiat Oncol Biol Phys 2002; 54: 1512-7.
26. Ciardiello F, Caputo R, Damiano V et al. Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin Cancer Res 2003; 9: 1546-56.
27. Williams KJ, Telfer BA, Stratford IJ, Wedge SR. ZD6474, a potent inhibitor of VEGF signaling, combined with radiotherapy: Schedule-dependent enhancement of anti-tumor activity in a lung tumor xenograft model. Proc Am Assoc Cancer Res 2003; 44: 8.
28. Wedge SR, Kendrew J, Ogilvie DJ et al. Combination of the VEGF receptor tyrosine kinase inhibitor ZD6474 and vascular-targeting agent ZD6126 produces an enhanced antitumor response. Proc Am Assoc Cancer Res 2002; 43: 1081.
29. Gieseler F, Rudolph P, Kloeppel G, Foelsch UR. Resistance mechanisms of gastrointestinal cancers: Why does conventional chemotherapy fail? Int J Colorectal Dis 2003; 18: 470-80.
30. Broxterman HJ, Lankelma J, Hoekman K. Resistance to cytotoxic and anti-angiogenic anticancer agents: Similarities and differences. Drug Resist Updat 2003; 6: 111-7.